DERM
Journey Medical Corporation
There isn't enough reported data to score DERM yet.
DERM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Strong |
DERM's revenue and balance sheet are currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow.
DERM PE Valuation
DERM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
DERM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect DERM to return to profit, with revenue growing. However, they disagree widely on these estimates.
DERM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.30 | — |
| Q3 2026 | -$0.18 | +$0.15 |
| Q2 2026 | -$0.22 | +$0.14 |
| Q1 2026 | -$0.37 | $0.00 |
| Q4 2025 | -$0.47 | +$0.25 |
| Q3 2023 | -$0.84 | +$2.61 |
| Q2 2023 | -$2.21 | +$1.83 |
| Q1 2023 | -$2.18 | +$2.73 |
| Q4 2022 | -$1.69 | +$3.11 |
DERM is still losing money, but far less than before: $0.18 per share over the past year, against $4.91 at its worst in early 2022.
DERM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +7.6% |
| Q2 2026 | $18.5M | +23% |
| Q1 2026 | $16M | +21% |
| Q4 2025 | $16.1M | +18% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $15M | +1% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $13.6M | -11% |
DERM's revenue is recovering but still below its 2023 peak: $19M last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.8% | +5.9 points |
| Q2 2026 | 2.5% | +22 points |
| Q1 2026 | -9.3% | +16 points |
| Q4 2025 | -2.8% | -19 points |
| Q3 2025 | -8.7% | +11 points |
| Q2 2025 | -19% | +0.5 points |
| Q1 2025 | -25% | +52 points |
| Q4 2024 | 16% | +30 points |
DERM's operating margin was −2.8% last quarter, up 5.9 points from the same quarter a year ago.
DERM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | -$1.1M |
| Q2 2026 | -$1.7M | -$792K |
| Q1 2026 | $2.9M | +$5.7M |
| Q3 2023 | $18.7M | +$26M |
| Q2 2023 | $4M | +$7.3M |
| Q1 2023 | -$6M | -774% |
| Q2 2022 | -$3.3M | +$4.1M |
| Q1 2022 | $884K | -35% |
DERM has burned cash in most quarters: −$5M over the past year, against −$2M the year before.
DERM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +575K shares |
| 1 year | +12% | +3.1M shares |
| 3 years | +33% | +7M shares |
| 5 years | +206% | +18.9M shares |
| Available history | -48% | -26.4M shares |
DERM has 28M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q3 2019 | $163,999 |
DERM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | 0.2x | Very low |
DERM has more cash than debt.
DERM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 7.6 | Oversold |
DERM's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
DERM PE vs Healthcare Sector
DERM has no meaningful PE right now: it lost money over the past year.
DERM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.38 | 18% below |
| 20 week MA | $6.38 | 31% below |
| 50 week MA | $6.65 | 34% below |
| 100 week MA | $6.59 | 33% below |
| 200 week MA | $5.14 | 15% below |
DERM is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
DERM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.50 | $5.70 | -40% |
| 2022 | $5.70 | $1.18 | -79% |
| 2023 | $1.18 | $5.76 | +388% |
| 2024 | $5.76 | $4.17 | -28% |
| 2025 | $4.17 | $7.92 | +90% |
| 2026 YTD | $7.92 | $4.39 | -45% |
DERM's yearly returns have swung widely, from +388% in 2023 to −79% in 2022. It's down 45% so far in 2026.